Inflammation: IBD COPD Asthma
Inflammatory response generally initiates by signals set-off by pathogen invasion or tissue injury. This, in turn, initiates the activation of intracellular signalling cascades and subsequently results in increased expression of proinflammatory pathways. When these responses persist despite resolution of the initial insult, these processes can become pathological. A wide spectrum of human diseases are associated with chronic inflammation and number of drugs have been used for the treatment of these inflammatory diseases. However, there still remain unmet needs due to several reasons and several limitations. Many current therapies are non-selective and associated with significant side effects limiting their tolerability. Furthermore, many patients become unresponsive to these first-line therapies.
Chronic inflammatory diseases, such as inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD) and asthma, pose a significant global economic and public health burden. Dysregulated immune responses underlie the disrupted homeostasis at mucosal barrier sites in the intestine and lungs in these conditions. We continue to search for new ways of addressing these unmet needs with advancing of our knowledge of the inflammatory pathways and their role in the pathophysiology of conditions.